Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IDXG Interpace Biosciences (IDXG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesTrends About Interpace Biosciences Stock (NASDAQ:IDXG) 30 days 90 days 365 days Advanced Chart Ad Stansberry Research"January Surprise" Could Cut Bull Run Short, Says Banking ExpertAccording to one of America's most trusted banking experts – followed by names at Wells Fargo, UBS, and Barclays – the U.S. economy could look very different by January 20. Click here to see Dan's warning (and possible solution) for America. Get Interpace Biosciences alerts:Sign Up Key Stats Today's Range$3.00▼$3.4650-Day Range$4.75▼$10.4052-Week Range$2.57▼$10.42Volume20,385 shsAverage Volume15,657 shsMarket Capitalization$14.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewInterpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.Read More… "January Surprise" Could Cut Bull Run Short, Says Banking Expert (Ad)According to one of America's most trusted banking experts – followed by names at Wells Fargo, UBS, and Barclays – the U.S. economy could look very different by January 20. Click here to see Dan's warning (and possible solution) for America. Receive IDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address IDXG Stock News HeadlinesPDI: Beware The Massive NAV PremiumNovember 13 at 5:02 AM | seekingalpha.comInterpace Biosciences Inc.November 9, 2024 | wsj.comPost-Election Bitcoin WarningAccording to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months... November 14, 2024 | Stansberry Research (Ad)Interpace Biosciences Reports Impressive Q3 2024 GrowthNovember 7, 2024 | markets.businessinsider.comInterpace Biosciences Announces Record Third Quarter 2024 Financial and Business ResultsNovember 4, 2024 | globenewswire.comPDI: The Big ROC Bath, 13.5% 'Yield'October 27, 2024 | seekingalpha.comInterpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to NasdaqOctober 15, 2024 | globenewswire.comHealthcare Stocks Pre-Market MoversOctober 13, 2024 | benzinga.comSee More Headlines IDXG Stock Analysis - Frequently Asked Questions How were Interpace Biosciences' earnings last quarter? Interpace Biosciences, Inc. (NASDAQ:IDXG) released its earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.26. The business services provider had revenue of $8.33 million for the quarter. Interpace Biosciences had a net margin of 10.39% and a negative trailing twelve-month return on equity of 8.09%. What other stocks do shareholders of Interpace Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Histogenics (HSGX). Company Calendar Last Earnings3/29/2023Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Services Current SymbolNASDAQ:IDXG CUSIP69329V10 CIK1054102 Webwww.interpace.com Phone855-776-6419Fax862-207-7820Employees152Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$800,000.00 Net Margins10.39% Pretax Margin10.93% Return on Equity-8.09% Return on Assets37.14% Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.53 Sales & Book Value Annual Sales$40.21 million Price / Sales0.36 Cash Flow$0.69 per share Price / Cash Flow4.73 Book Value($13.11) per share Price / Book-0.25Miscellaneous Outstanding Shares4,400,000Free Float4,157,000Market Cap$14.43 million OptionableNot Optionable Beta0.62 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:IDXG) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredIs Your 401(k) Safe? The Real Risk No One Sees ComingEvery day you wait, your savings are at greater risk. The government isn't slowing down, inflation isn't stopp...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.